# Kalypsys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kalypsys

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.kalypsys.com
- Total disclosed funding: $172M
- Latest round: Series C (Nov 29, 2006)
- Investors on record: 9

## About

Kalypsys operates a digital healthcare platform that facilitates the appointment scheduling process for patients seeking specialized care from healthcare providers, including various specialists and therapists.Founded in 2001 in San Diego, US, Kalypsys offers a platform for connecting patients with healthcare providers. The company has undergone strategic pivots since its inception, transitioning into a digital health service. Kalypsys was pivotal in the healthcare sector by raising USD 100 mn in Series C funding in November 2006, led by Tavistock Group along with other investors. The company has completed 3 deals in total, and its current valuation stands at USD 251.857 mn.Kalypsys provides a digital healthcare platform designed to streamline the process of finding and scheduling appointments with healthcare providers. The service focuses on common pain conditions, enabling patients to book both in-person and telemedicine appointments with specialists like orthopedic surgeons and neurologists. The platform is available in major urban centers, including New York City, Brooklyn, and Queens, targeting patients and healthcare providers alike.Kalypsys generates revenue through a transaction-based model, charging service fees for each appointment booked through its platform. This fee structure varies by consultation type, whether in-person or telemedicine, and aligns with the competitive healthcare market. The platform also supports B2C transactions and B2B partnerships with healthcare providers, facilitating access to quality care for its users.Following the recent Series C financing raised in November 2006, Kalypsys plans to utilize the USD 100 mn to enhance its product offerings and expand into new markets. Specific regions targeted for growth include additional urban centers across the US, focusing on areas with high demand for specialized healthcare services. Future initiatives may include developing new features for their platform aimed at improving user experience and expanding service provider partnerships.

## Funding rounds

- Series C, Nov 29, 2006, $100M — Sprout Group, Presidio Partners, Tavistock Group, KT Venture Group
- Series B, Aug 4, 2004, $29M — Sprout Group, Aravis, Novartis Venture Fund, Presidio Partners, 5AM Ventures, Invemed Associates, Tavistock Group, KT Venture Group
- Series A, Apr 2, 2002, $43M — Sprout Group, Aravis, Novartis Venture Fund, Presidio Partners, SG Growth Capital, Tavistock Group

## Investors

- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series A, Series B, Series C
- Aravis (https://capitalatlas.ai/funds/aravis) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Presidio Partners (https://capitalatlas.ai/funds/presidio-partners) — Series A, Series B, Series C
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series A
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series A, Series B, Series C
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series B
- Invemed Associates (https://capitalatlas.ai/funds/invemed-associates) — Series B
- KT Venture Group (https://capitalatlas.ai/funds/kt-venture-group) — Series B, Series C